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Abstract
AIM: Thiazolidinediones (TZD) are a new class of oral
antidiabetic drugs that have been shown to inhibit growth
of same epithelial cancer cells. Although TZD were found
to be ligands for peroxisome proliferator-activated
receptor  (PPAR), the mechanism by which TZD exert
their anticancer effect is presently unclear. In this study,
we analyzed the mechanism by which TZD inhibit growth
of human pancreatic carcinoma cell lines in order to
evaluate the potential therapeutic use of these drugs in
pancreatic adenocarcinoma.
METHODS: The effects of TZD in pancreatic cancer cells
were assessed in anchorage-independent growth assay.
Expression of PPAR was measured by reverse-transcription
polymerase chain reaction and confirmed by Western blot
analysis. PPAR activity was evaluated by transient reporter
gene assay. Flow cytometry and DNA fragmentation assay
were used to determine the effect of TZD on cell cycle
progression and apoptosis respectively. The effect of TZD
on ductal differentiation markers was performed by
Western blot.
RESULTS: Exposure to TZD inhibited colony formation in
a PPAR-dependent manner. Growth inhibition was linked
to G1 phase cell cycle arrest through induction of the
ductal differentiation program without any increase of the
apoptotic rate.
CONCLUSION: TZD treatment in pancreatic cancer cells
has potent inhibitory effects on growth by a PPAR-dependent
induction of pacreatic ductal differentiation.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Pancreatic cancer is a devastating disease characterized by
an increased incidence in western industrialized countries,
an extremely poor median survival of  4-6 mo after diagnosis[1],
and limited therapeutic options[2].
The majority of pancreatic cancers arises from the
pancreatic duct cells and is characterized by uncontrolled
growth, inability to express the differentiated features of
normal duct cells and progressive accumulation of  multiple
genetic abnormalities[3].
It has been suggested that the pharmacological induction
of cellular differentiation might be an alternative to
conventional tumor chemotherapy. The activation of the
terminal differentiation program in genetically abnormal
tumor cells is strictly associated with irreversible growth
arrest[4]. In pancreatic cancer cells, retinoids, for example,
induce differentiation and inhibit growth by activation of
their specific nuclear receptors[5,6] suggesting that other
nuclear receptors involved in the regulation of cellular
differentiation might be targets for novel therapeutic
strategies of pancreatic cancer.
Thiazolidinediones (TZD) such as pioglitazone (PGZ)
and rosiglitazone (RGZ) are a new class of antidiabetic drugs,
which attenuate the insulin resistance associated with obesity,
hypertension and impaired glucose tolerance in humans as
well as in several animal models of non-insulin-dependent
diabetes mellitus[7]. TZD were found to be ligands for
peroxisome proliferator-activated receptor  (PPAR), a
member of the nuclear receptor superfamily of ligand-
dependent transcription factors that is predominantly
expressed in adipose tissue although it is also expressed in
other tissue at much lower levels[8-10]. In adipose tissue
PPAR functions as a master regulator of  adipogenesis and
its ligand-mediated activation in fibroblasts induces adipocyte
differentiation and lipid storage[11,12]. TZD activate PPAR
and promote association with 9-cis retinoic acid receptor
(RXR) to form functional heterodimers, which recognize their
cognate response element at the level of target genes[13,14].
Several recent studies have indicated that TZD may
have anticancer properties in a variety of different epithelial
malignancies including breast, prostate and gastrointestinal
cancers[15-17]. Treatment of  cultured breast and colon cancer
cells with TZD resulted in a reduction in growth rate and
induction of  apoptosis[18,19]. Furthermore, human colorectal
cancer cells implanted in nude mice were shown to grow
more slowly in mice treated with TZD, with a 50% reduction
of tumor volume[20]. In addition loss-of-function mutation
of  the PPAR gene has been found in some human colon
and thyroid carcinomas[21,22]. As a consequence, PPAR has
become a molecular target for anticancer drug development,
and TZD have been proposed for therapy of  PPAR-
expressing tumors.
Although preliminary evidence has shown that, troglitazone,
the first TZD marketed for use in humans, inhibited pancreatic
cell proliferation[23,24], the mechanism by which these drugs
inhibit cell growth in these cells has not been conclusively
established.
In this study we demonstrated that exposure of pancreatic
cancer cells to TZD inhibited anchorage-independent
growth with a PPAR-dependent differentiation-inducing
mechanism. Surprisingly the ductal pro-differentiation
program induced by PPAR activation was not associated
with apoptosis in these cells.
MATERIALS AND METHODS
Materials
Most chemicals and supplies were purchased from Sigma
Chemical Company (St. Luis, MO). Nitrocellulose and
Nytran were from Schleicher and Schuell, Inc., (Keene, NH).
Agarose, trypsin, all restriction endonucleases, DNA-
modifying enzymes, and tissue culture media were purchased
from Gibco BRL (New Brunswick, NJ). Fetal bovine
serum (FBS) was from HyClone Laboratories (Logan, UT).
D-threo-[dichloroacetyl-1,2-14C]-chloramphenicol was
purchased from New England Nuclear (Boston, MA).
Rosiglitazone and pioglitazone were from SmithKline
Beecham Pharmaceuticals (Welwyn, UK) and Takeda
Chemicals (Tokyo, Japan) respectively.
Tissue sample and cell cultures
The pancreatic adenocarcinoma cell lines PANC-1,
CAPAN-2, and HPAC were obtained from the American
Type Culture Collection (ATCC, Rockville, MD). Cells
were maintained in Dulbecco’s modified Eagles medium
(DMEM; GIBCO Laboratories, Grand Island, NY)
containing 10% fetal bovine serum (FBS, Gibco). Culture
medium was supplemented with 50 U/mL penicillin and
50 g/mL streptomycin. All experiments were performed
in phenol red-free medium.
Tumor clonogenic assay
Pancreatic cancer cells were trypsinized and disaggregated
through a 19-gauge needle into a single-cell suspension, as
evaluated by microscopy. Cells 2×104 were mixed with
DMEM/5% dialyzed FBS containing 0.3% agarose and
TZD at the concentration indicated. Cells were then layered
over a solid base of 0.5% agarose in the same medium, in
60-mm dishes. The cultures were incubated in humidified
50 mL/L CO2/95% air at 37 ℃. After 14 d the colonies
were counted by an Omnicon 3 600 Colony Counter and
photographed.
Cell cycle analysis
Cells (4×105) were exposed to TDZ for 4 d in medium
supplemented with 5% dialyzed FBS. Total cells both in
suspension and adherent, were collected, washed, suspended
in cold PBS, and stained in trypan blue. Both blue and non-
blue cells were counted. The cells were adjusted to 1×106
viable cells/mL and fixed in 2:1 ratio (v/v) in methanol
overnight before staining with propidium iodide. Cell cycle
status was analyzed with Becton Dickinson Flow Cytometer
and CellFIT Cell-Cycle Analysis software.
Protein extract and Western blot
Whole-cell proteins were extracted from the different
adenocarcinoma cell lines. Cells were cultured in the presence
or absence of test agents and were homogenized in Laemmli
buffer[25]. Nuclear proteins were isolated from treated and
untreated cells based on micro preparation methods[26].
The nuclear extracts were suspended in 20 mmol/L HEPES
(pH 7.9), 40 mmol/L NaCl, 1.5 MgCl2, 0.2 mmol/L
ethylenediaminetetraacetic acid, 25% glycerol, 0.5 mmol/L
dithiothreitol, and 0.2 mmol/L phenylmethylsulfonyl
fluoride. Lysates were centrifuged at 20 000 g for 10 min
at 4 ℃ and supernatants were frozen in liquid nitrogen and
stored at -80 ℃ until use. Nuclear and whole-cell extracts
(40 g protein) were fractionated in 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and electro blotted
onto nitrocellulose filters. Proteins were detected by
incubating the filters with the following primary antibody:
mouse anti-human PPAR (1:500) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), sheep anti-human carbonic anhydrase
II (1:500)[27] cytokeratin 7 (1:1 500) (Novocastra Lab,
Newcastle UK), p21 (1:1 000) (Santa Cruz Biotechnology,
Santa Cruz, CA) and p27 (1:1 000) (Santa Cruz Biotechnology,
Santa Cruz, CA), mouse anti-human bcl-2, bax, and bcl-xl
(1:1 000) (Transduction, Laboratories, San Diego CA)
mouse anti human bax (1:1 000), and mouse anti-human
bak (1:1 000) (CalBiochem, San Diego CA). Detection of
the protein bands was performed using the Amersham ECL
kit (Arlington Heights, IL).
RNA extraction and RT-PCR
Total RNA was extracted from cultured cells and by
guanidinium-phenol-chloroform methods of  Chomczynski
and Sacchi[28] with minor modifications[29]. One mg of RNA
from tumor cells was reverse transcribed with Molony
murine leukemia virus (MMLV) reverse transcriptase (Life
Technologies Inc., Paisley, UK) at 42 ℃ for 60 min in a 20-L
mixture in the presence of random hexamers. The nucleotide
bases used for human PPAR were 5’-TCTGGCCCACC-
AACTTTGGG-3’  and 5 ’-CTTCACAAGCATGA-
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ACTCCA-3’. Two L of  a reverse-transcribed mixture was
subjected to PCR in a 20-L reaction solution [10 mmol/L
Tris-HCl (pH 8.3), 50 mmol/L KCl, 2.0 mmol/L MgCl2,
0.01% gelatin, 20 mmol/L deoxynucleotide triphosphate,
0.5 units of  Taq polymerase (Life Technologies Inc., Paisley,
UK), and 0.25 pmoL of  primers]. Twenty-five cycles of
reaction at 94 ℃ for 50 s, 60 ℃ for 45 s, and 72 ℃ for 90 s
were carried out by DNA thermal cycler (Perkin-Elmer
Cetus Norwalk, CT). Efficiency of RT was controlled in
each sample by PCR amplification of human  2-
microglobulin (5’-GCAAAAGATGAGTATGCCTG-3’, 5’-
TTCACTCAATCCAAATGCGG-3’).
Transient transfection of culture cells
Cells were transfected at the density of 5×105 cells/60 mm
dish with 2.5 g of peroxisome proliferator response element
(ARE)3-tk-luciferase reporter plasmid (containing 3 copies
of the PPRE from the adipocyte lipid-binding protein (aP2)
gene ligated to a herpes simplex thymidine kinase promoter
upstream of a luciferase gene)[30,31], and 5 g of pSV2CAT
(vector containing SV40 early promoter and enhancer
sequences that drives a chimeric chloramphenicol acetyl
transferase [CAT] gene) as an internal control by calcium
phosphate precipitation. Total amount of  DNA transfected
was normalized with a carrier DNA (pcDNA3.1; Invitrogen
Corporation, Carlsbad, CA). Four hours later the cells were
exposed to PBS containing 15% glycerol for 3 min. The
cells were rinsed twice with PBS and fresh serum
supplemented with 5% dialyzed FBS was added. Twenty
four hours after transfection cells were treated with TZD.
Twenty four hours later, the cells were harvested, washed
twice with PBS, and lysed in 150 L of buffer containing
25 mmol/L Tris, pH 7.8, 2 mmol/L ethylenediaminetetraacetic
acid, 20 mmol/L dithiothreitol, 10% glycerol, and 1% Triton
X-100. Fifty microliters of cell extract were incubated with
luciferase assay reagent based on the original protocol of
de Wet et al[32]. The number of  relative light units with a 3-
s delay and 30-s incubation were measured by Sirius1
luminometer (Berthold Detection System, Pforzheim/
Germany). CAT activity was measured as described
previously[33]. The conversion of chloramphenicol to its
acetylated products was quantified on Ambis beta scanner
(Ambis System, San Diego, CA).
Generation of the PPAR-expressing cell line
Human PPAR cDNA was cloned into pLNCX, a retroviral
vector driving expression of the cloned cDNA from the
cytomegalovirus promoter and conferring resistance to
G418. Retrovirus plasmid was transfected into a packaging
cell line, PA317, and used to transduce HPAC cells as
previously described[34]. In brief, PA317 were transfected
with 10 g of  the cloned construct (PPAR-pLNCX) or
the empty retroviral vector, using calcium phosphate
precipitation followed by glycerol stock as described above.
Twenty four hours after transfection the virus-containing
supernatant was removed, filtered through a 45-m filter,
and stored at -70 ℃. A total of  5×105 HPAC cells were
infected with 106 cfu/mL virus in the presence of 6 g/mL
polybrene. Twenty four hours later the cells were replated
in duplicate and selected with 600 g/mL of the antibiotic
G418. After selection of G418-resistant cells, the clones
were expanded and screened for PPAR expression by
Western blotting.
Apoptosis assay
Following the indicated treatments, apoptosis was measured
by a DNA fragmentation assay (Apo-Direct) as recommended
by the manufacturer (PharMingen, San Diego, CA). Briefly,
cells (adherent and floating) were fixed in 1% formaldehyde
in PBS overnight. After washing, 106 fixed cells were
incubated with terminal deoxynucleotidyl transferase enzyme
(TdT) and FITC-dUTP for 90 min at 37 ℃ to label DNA
breaks. Cells were rinsed, incubated in RNaseA/propidium
iodide in the dark for 30 min at room temperature to stain
total DNA, and then analyzed by flow cytometry. Cells
doublets and clumps were eliminated from the analysis by
gating.
Statistical analysis
Data was expressed as mean±SD. Statistical correlation of
data was checked for significance by ANOVA and paired
Student’s t test. The corresponding probability (P) is given.
RESULTS
TZD inhibited anchorage-independent growth of human
pancreatic cancer cells with a PPAR-dependent mechanism
We initially investigated the effect of  TZD on pancreatic
cancer cell growth. The effect of TZD on anchorage-
independent growth was assessed by cloning cancer cells in
soft agarose. Treatment with both TZD at the concentration
of 10 mol/L resulted in a significant inhibition of colony
formation by Panc-1 and Capan-2 cell lines, whereas drug
treatment was ineffective in the PPAR non-expressing
HPAC cells (Figure 1A, B). Clofibric acid was used as a
negative control. The dose dependency for the anchorage-
independent growth inhibition was further characterized in
Panc-1 cells. PGZ inhibited colony formation in a dose-
dependent manner in Panc-1 cell line (Figure 1C). Moreover,
the size of the colonies was significantly smaller in the RGZ-
treated cells compared to cells treated with vehicle alone.
To confirm the role of  PPAR in TDZ-induced growth
arrest, we generated a PPAR-expressing HPAC cells using
transducing retroviruses. Four isolated HPAC clones showed
selective overexpression of  PPAR protein compared to
parental wild type and mock-transfected controls (Figure 2A).
Of  the selected clones, number 3 (P3-HPAC) was used for
further studies. In these cells, PGZ induced the activity of
the ARE-73-tk-luc reporter in a dose-dependent manner
(Figure 2B) and this effect was correlated to a significant
inhibition of anchorage-independent growth (Figure 2C).
PPAR activation by TZD alters cell cycle progression but
does not induce apoptosis in pancreatic cancer cells
Preliminary experiments evaluating trypan blue exclusion
and lactate dehydrogenase leakage from pancreatic cancer
cells into the culture medium showed that both TZD induced
growth inhibition rather than cytotoxicity, because the
number of vitally stained cells was higher than 90% in all
experiments at any given time point. Based on this observation,
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we assessed the effect of RGZ and PGZ on cell cycle
progression. Little change in cell distribution was observed
at 12 h with 20 mol/L of TZD in all cell lines (not shown).
In PPAR-expressing cells both RGZ and PGZ increased
the proportion of cells in G0/G1 phase at 24 h and the
arrest persisted at later time points (Figure 3). The Increased
number of cells in G0/G1 phase was mirrored by a
proportional decrease of cells in S phase. No effect was
Figure 1  Effect of TZD on anchorage-independent growth in human pancreatic adenocarcinoma cells. A: PPAR expression in human
pancreatic adenocarcinoma. One microgram of total RNA extracted from three pancreatic cancer cell lines (Capan-2, Panc-1, and HPAC) was
reverse transcribed using random hexamers and amplified by polymerase chain reaction using specific primers for PPAR and for 2-microglobulin
(2-M) as described in Methods. The reverse-transcription polymerase chain reaction products were electrophoresed on ethidium bromide-
containing agarose gel; B: TZD inhibit anchorage-independent growth. 2x104 cells were plated into media containing 0.3% agarose, supple-
mented with either 10 µmol/L of TZD (RGZ o PGZ), or 1 mmol/L clofibrate (CA). After 14 d the number of colonies was determined and then
expressed as the percentage of control cells treated with vehicle (DMSO) alone. The mean±SD of six independent experiments performed for
each cell line in triplicate are shown. aP<0.05 (or higher degree of significance) vs control; C: Dose-dependent inhibition of anchorage-
independent growth by TZD in Panc-1 cells. Clonogenic assay of Panc-1 cells treated with the indicated concentrations of RGZ was performed as
described in Methods. The number of colonies was then given as the percentage of control cells treated with vehicle alone. The mean±SD of five
independent experiments performed for each in triplicate are shown. aP<0.05 (or higher degree of significance) vs control.
Figure 2  PPAR expression and transcriptional activity in HPAC cells transduced with PPAR-expressing retrovirus. A: HPAC cells were
stable transduced by retrovirus driving expression of human PPAR (hPPAR-pLNCX) as described in methods. After selection with G418 four
resistant clones were expanded and screened for hPPAR expression. The cell extracts were fractionated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and blotted to nitrocellulose. The proteins (40 g) were detected with antibody raised against human
PPAR. P1-P4 represent nuclear protein extracted from G418-resistant HPAC cell clones; M represents nuclear proteins from mock (pLNCX)
transduced HPAC cells; W (wild type) represents nuclear proteins from untransduced, parental HPAC cells; B: After overnight attachment
cells were transfected with ARE-73-tk-luciferase reporter plasmid and pSV2-CAT as internal control for transfection efficiency. Twenty-four
hours after transfection cells were treated with RGZ at the indicated concentration. Twenty-four hours after treatment the cells were
harvested for luciferase and CAT assay as described in Methods. The data is expressed as mean±SD for 4 replicate experiments performed
in triplicate; aP<0.05 vs control; C: Effect of TDZ treatment on anchorage-independent growth of HPAC cells transduced with PPAR -
expressing retrovirus. Clonogenic assay of P3-HPAC cells treated with the indicated concentration of RGZ was performed as described in
materials and methods. The number of colonies was then given as the percentage of control cells treated with vehicle alone. The mean±SD
of five independent experiments performed for each in triplicate are shown. aP<0.05 vs Mock transduced cells.
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documented in the PPAR-deficient HPAC line, whereas
the inhibition of cell cycle progression by TZD was restored
in P3-HPAC cells. To determine whether the inhibitory effect
of TZD was in part mediated by inducing apoptosis, cells
were treated with RGZ or PGZ for 72 h before the analysis.
The extent of apoptosis was measured by incorporation of
FITC dUTP in the presence of TdT enzyme to detect DNA
fragmentation. Both compounds had negligible effect on
the extent of apoptosis at the higher concentration used
(Table 1). In addition, the expression of  the bcl-2 family
members involved in regulating apoptosis was also
determined in PANC-1, Capan-2 and P3-HPAC cells
following treatment with RGZ or PGZ. After 24-h
incubation with TZD, no change in the expression of the
inducers of apoptosis, bax or bak, or inhibitors of apoptosis
such as bcl-2 and its close homologue bcl-xL was detected
(Figure 4). These results suggest that pancreatic tumor cells
are relatively resistant to apoptosis induced by TZD.
Table 1  Effect of TZD on apoptosis in pancreatic tumor cells. Extent
of apoptosis following treatment of pancreatic cancer cell lines with
20 mol/L of TZD (RGZ or PGZ) for three days was measured by the
incorporation of FITC-dUTP in the presence of TdT enzyme to detect
DNA fragmentation as described in Methods. Cells were stained
with RNase A/PI and analyzed by flow cytometry. The mean±SD of
five independent experiments each performed in triplicate are shown
Apoptosis (%)
Treatment
               Panc-1       Capan-2  HPAC        P3-HPAC
Control (DMSO)             1.16±0.15      0.88±014            0.46±0.19         0.66±017
RGZ             1.20±0.17      0.90±0.22           0.38±0.17        0.58±0.19
PGZ             1.19±0.14      0.93±0.17           0.40±0.18         0.57±0.13
Figure 4  Expression of apoptotic proteins in cells treated with TZD.
Sub-confluent cells were treated with 20 mol/L of TZD (RGZ or PGZ)
for 24 h. Cells were then harvested, and whole-cell protein extracts
were fractionated by sodium dodecyl sulfate-polyacrylamide elec-
trophoresis and transferred to nitrocellulose paper as described in
Methods. Different proteins were detected by incubating the filter
with specific antibodies.
TZD promoted differentiation and reversal of the transformed
phenotype in PPAR-expressing cells
In the PPAR-expressing cell line, PANC-1, 72-h incubation
with RGZ resulted in morphological changes with more
abundant, flattened cytoplasm, and increased cytoplasmic/
nuclear ratio, as is consistent with a more mature phenotype
(Figure 5B). To determine whether morphological changes
and growth arrest were accompanied by differentiation,
analysis of  markers of  the differentiated state was performed.
Treatment with 20 mol/L of  RGZ resulted in a time-
dependent increased expression of ductal specific markers
such as carbonic anhydrase II (CA II)[5] and cytokeratin 7[35]
as well as “general” differentiation markers such as the cell
cycle inhibitors p21 and p27 (Figure 5A). Expression of
Figure 3  Cell cycle phase distribution of pancreatic tumor cells treated with TZD. After overnight attachment cells were treated with
20 mol/L of TZD (RGZ or PGZ) for 72 h, followed by staining with propidium iodide and flow cytometric analysis of DNA content. The
percentage of cells in each cell cycle phase was determined by analysis of the DNA content histograms using Modfit software as described
in Methods. Data show the percentage of cells in each phase of cell cycle in a representative experiment. Similar results were obtained in
at least three independent experiments.
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-actin, used as an internal control, did not change under
any experimental condition. Treatment with PGZ had similar
effect (not shown). In contrast, HPAC cells did not show
any induction of differentiation markers (Figure 6A). TZD
induced p21 and CA II expression in the P3-HPAC clone
(Figure 6B), thus supporting the role of  PPAR in the
acquisition of a more differentiated state.
Because PPAR activation can enhance adipocyte
differentiation[11], we examined the lipid accumulation in
PANC-1 and in Capan-2 cells. Oil Red O staining revealed
no lipid accumulation after PGZ or RGZ treatment for 4 d
(not shown).
DISCUSSION
Here we studied the effects of two TZD, pioglitazone
(PGZ) and rosiglitazone (RGZ), on pancreatic cancer cell
growth, and we characterized the relationship between
PPAR expression and their anticancer properties. The two
TZD similarly induced a strong inhibition of anchorage-
independent growth on PPAR-expressing cell lines but
they had no effect on colony formation of  the PPAR-
deficient cells, HPAC (Figure 1B). The role of  PPAR in
the antiproliferative effect of TZD in pancreatic cancer
cells was confirmed by overexpression of  the receptor in
HPAC cells. Expression of  PPAR in HPAC cells, obtained
by transducing retrovirus, restored the growth inhibitory
effect of TZD in parallel with a significant induction of
PPRE reporter activity (Figure 2B, C). We therefore,
conclude that PPAR expression determines TZD sensitivity
in pancreatic carcinoma cells. Confirming our result, the
reduction of DNA accumulation by RGZ in glioma cells is
strictly dependent on PPAR expression[36]. In addition RGZ
exclusively inhibits anchorage-independent growth in human
colorectal cancer cells that express a transcriptionally active
PPAR[18]. This data is, however, partially in contrast with
the observation that the anticancer effects of  TZD are
independent of  PPAR and mediated by inhibition of
translation initiation[37]. In fact, in PPAR ES cells troglitazone
induced cell cycle arrest by partial depletion of intracellular
Ca2+ stores, activation of the double-stranded RNA-
dependent protein kinase (PKR), and phosphorylation of
the eukaryotic initiation factor 2 (eIF2). Furthermore,
Abe et al have indicated that troglitazone suppressed cell
growth and histamine secretion by a PPAR-independent
mechanism in the human basophilic leukemia cell line
KU812[38]. A possible explanation of this controversy may
be due to the different chemical structure of the various
members of TZD family. Only troglitazone, for instance,
has the chroman structure of  vitamin E, suggesting that this
TZD could regulate signal pathways by mimicking the effects
of  vitamin E and independently of  PPAR transcriptional
Figure 5  TZD-induced ductal differentiation in pancreatic adenocarcinoma cells. A: Effect of RGZ on the expression of differentiation
markers in Panc-1 cells. After 24 h of plating, cells were incubated with 20 mol/L of RGZ for the indicated time intervals. Protein extracts
were then extracted and separated by Western blotting as described in Methods. Immunoreactive proteins were detected by incubating the
filters with the specific primary antibodies. A representative of three independent experiments, yielding similar results, is shown; B: Effect
of RGZ on tumor cells morphology. Panc-1 cells were plated onto sterile culture chambers and then treated with 20 mol/L of RGZ for 96 h.
After the incubation period cells were photographed with Axiovert 200 Image System (Zeiss, Gottingen, Germany). Original magnification ×200.
Figure 6  Effect of TZD on expression of differentiation markers in HPAC cells transduced with PPAR-expressing retrovirus. Untransduced
parental HPAC cells. A: or PPAR-overexpressing P3-HPAC cells; B: were incubated with 20 mol/L of RGZ for the indicated time intervals.
Protein extracts were then extracted and separated by Western blotting as described in Methods. Immunoreactive proteins were detected
by incubating the filters with the specific primary antibodies. A representative of three independent experiments, yielding similar results, is
shown.
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activation[39].
To define the mechanisms by which TZD inhibit the
growth of pancreatic carcinoma cells, we analyzed the cell
cycle profile of cells treated with RGZ and PGZ. Both
TZD increased the population of cells in G1/G0 phase and
reduced the population of  cells in S phase in PPAR-
expressing cells (Figure 3). These results support recent
observations in other growing cells, such as colon cancer
cells and myeloid leukemia cells, showing that PPAR
activation induce G1 cell cycle arrest[18,40]. These cycle
alterations were achieved at TZD concentrations that
repressed pancreatic cell growth, indicating that cell-cycle
arrest is one of the primary mechanisms responsible for
the anti-proliferative action of TZD in pancreatic cancer
cell in vitro.
Apoptosis and cell differentiation are tightly linked to
cell cycle control mechanisms, particularly those that regulate
the transit through G1 phase[41,42]. Thus, the induction of G1
arrest by TZD-activation of  PPAR may be the precipitating
molecular events for subsequent cell differentiation or death.
We did not find any pro-apoptotic effects in PPAR-
expressing and non-expressing cells after TZD treatment at
the highest concentration used (Table 1 and Figure 4),
whereas a significant time-dependent induction of both
general and ductal-specific differentiation markers was
observed after TZD treatment in PANC-1 cells and in the
PPAR overexpressing clone, P3-HPAC. This suggests that
the in vitro anti-proliferative effects of TZD in pancreatic
tumor cells are not primarily mediated by the induction of
apoptotic cell death. Our findings are consistent with the
apoptotic-resistant phenotype characteristic of pancreatic
tumor cells that are resistant to undergoing apoptosis induced
by chemotherapeutic agents, activation of surface receptors
such as CD 95 or by serum and growth factor withdrawal[43,44].
Similarly to TZD, non-steroidal anti-inflammatory drugs
(NSAID) such as indomethacin and sulindac inhibit
pancreatic cell growth by cell-cycle arrest without apoptosis
via a COX2-independent mechanism[45]. Interestingly, it has
been shown that NSAID are PPAR activators and their
growth-inhibitory effect in pancreatic cells could be mediated,
at least in part, by this receptor[46]. Furthermore, Wick et al,
have recently demonstrated that PPAR is one of  the molecular
targets of  NSAID mediating COX-independent inhibition
of  lung cancer cell growth[47]. In contrast, the natural PPAR
ligand, 15d-PGJ2, induced substantial apoptosis in pancreatic
cancer cells[48]. These discrepancies could be explained
assuming that the effect of 15d-PGJ2 may be partially
PPAR-independent. Indeed, cyclopentenone prostaglandins
have been shown to induce apoptotic cell death of human
hepatic myofibroblasts, which do not express PPAR, by a
mechanism involving the production of reactive oxygen
species[49]. Furthermore, specific inhibition of  PPAR does
not prevent 15d-PGJ2-induced apoptosis in breast cancer
cells, suggesting that this ecosanoid requires mechanisms
others than activation of  PPAR to induce apoptosis[50].
Although inhibition of cloning efficiency is generally
considered the hallmark of differentiation, we investigated
additional characteristics that would point towards a more
differentiated phenotype of ductal carcinoma cells. Whereas
much is known about PPAR and its role in adipocytic
differentiation[11], in part because of the identification of
well-established markers of  the terminally differentiated
adipocyte[12], the pancreatic ductal epithelium represents a
more complex and challenging system. We found that TZD
treatment induced the expression of differentiated ductal
cells markers such as CK-7[35] and CAII[5] in parallel with a
significant up-regulation of the cell cycle inhibitors p21 and
p27 in Panc-1 cells (Figure 5A). By light microscopy, we
observed elongation and flattening of  cells with extending
cellular process after TZD treatment (Figure 5B). These
morphological changes are strikingly similar to the ones
observed after butyrate and retinoid induced differentiation
in the same cell lines[5,51] and represented a more differentiated
and less malignant state. In agreement with the negligible
effect of  TZD on growth of  PPAR non-expressing cells,
these drugs have no effect on the expression of CAII and
p21 in HPAC cells (Figure 6A). Ectopic expression of  PPAR
completely restored the ability of TZD to induce ductal
differentiation in HPAC cells, suggesting that the expression
and activation of  PPAR pathway is a key step in pancreatic-
specific differentiation (Figure 6B). Chang et al, have recently
reported growth inhibition and increased expression of
markers of bronchoalveolar progenitor cells in non-small
cell lung cancer after treatment with PPAR agonists[52].
Similarly to our results, they did not document either lipid
accumulation or adipocyte-specific gene expression, thus
excluding adipocytic transdifferentiation of these cell lines.
The signaling events evoked by PPAR activation in epithelial
cancer cells remain unclear. The ability of TZD to establish
various lineage-specific differentiated states that differ
according to the cellular type would suggest that the PPAR
pathway functions early in the induction of differentiation,
before lineage-specific events occur.
Overall, our study demonstrates that TZD inhibits
growth of  pancreatic cancer cells via a PPAR-dependent
induction of ductal differentiation. Given the favorable
toxicity profile of these drugs and the limited treatment
options that are currently available for patients with pancreatic
malignancies, TZD might be a new effective approach to
complement conventional chemotherapeutic regimens for
pancreatic cancer therapy.
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